�
According to a study published on bmj.com, most
genus Cancer patients make a decision about treatment with small or no
information about the endurance benefits of palliative chemotherapy.
Palliative chemotherapy is a way to boil down the austereness of symptoms for
patients with advanced cancer. Though it is not designed to cure the
crab, the therapy has meek survival gains, of months rather than
years, for patients in advanced stages of malignant neoplastic disease. In the UK, it is
expected that doctors provide accurate information to patients so an
informed decision can be made before initiating chemotherapy.
Researchers from the University of Bristol, however, have found that
over 66% of genus Cancer patients remained uninformed and did not receive
information about the survival benefits of palliative chemotherapy.
They assessed the cases of 37 patients - with colorectal, non-small
cell lung, or pancreatic cancer - at a big teaching infirmary or a
district general hospital in the south west of England. All of the
patients had advanced cancer, and permitted digital recording of their
consultations with oncologists. In order to analyze how survival put on
was discussed when patients were offered palliative chemotherapy, the
researchers utilized data from ASPECTS - a study of patients' of
experiences treatments. Before the patient met with the oncologist, a
researcher interviewed the patient. The researcher then recorded the
consultation with the health professional and followed-up one more than time
with the patient role within the following weeks.
The investigators found that physicians were consistent in informing
patients that they were past the point of a cure and one was not being
sought for them. However, there was considerable variance in how much
information about survival benefits from palliative chemotherapy was
tending. Some
patients received numerical data ("about little Joe weeks") while other
standard an idea of timescale ("a few months extra"), vague references
("buy you some time"), or nix at all. Of the 37 patients, six were
provided with numerical information about the treatment's survival gains. Most
of the consultations, 26 of 37, resulted in a vague discussion of
natural selection benefits or in no discussion at all.
It is possible, according to the researchers, that the "intrusiveness
of unfavorable numbers," such as the turn of months or weeks left to
live, undermines a doctor's relationship with her patient and
engenders a negative state. "Giving comprehensible and appropriate
information about survival benefit is extremely difficult. In addition,
the hesitancy to inform patients of the limited survival advance of
alleviator chemotherapy may be motivated by a desire to 'protect'
patients from tough news," write the authors. "However, the reluctance to
address these difficulties and sensitivities may be hampering patients'
power to make informed decisions about their future treatment."
The researchers intimate that oncologists and genus Cancer teams should
sensitively communicate enough data that can help a patient construct
an informed, realistic decision. In addition, they advocate training
for oncologists to help them better pass along survival information to
patients.
What oncologists tell patients about endurance benefits of
palliative chemotherapy and implications for informed consent:
qualitative studySuzanne Audrey, Julian Abel, Jane M Blazeby, Stephen Falk,
Rona Campbell
BMJ (2008). 337: a752.
doi:10.1136/bmj.a752
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News TodayMore info
